JUPITER NEUROSCIENCES, INC. Amortization of Debt Discount (Premium)
JUPITER NEUROSCIENCES, INC. (JUNS) reported Amortization of Debt Discount (Premium) of $43.29 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2026-04-01.
Financial Statements › Cash Flow › Operating Activities
us-gaap:AmortizationOfDebtDiscountPremium · last filed 2026-04-01
- JUPITER NEUROSCIENCES, INC. amortization of debt discount (premium) for the quarter ending 2024-12-31 was $28.27K, a 460.90% increase year-over-year.
- JUPITER NEUROSCIENCES, INC. amortization of debt discount (premium) for the quarter ending 2024-09-30 was $5.04K.
- JUPITER NEUROSCIENCES, INC. amortization of debt discount (premium) for the quarter ending 2024-06-30 was $4.99K.
- JUPITER NEUROSCIENCES, INC. amortization of debt discount (premium) for the quarter ending 2024-03-31 was $4.99K.
- JUPITER NEUROSCIENCES, INC. amortization of debt discount (premium) for fiscal 2024 was $43.29K, a 159.02% increase from fiscal 2023.
- JUPITER NEUROSCIENCES, INC. amortization of debt discount (premium) for fiscal 2023 was $16.71K.
| Period end | Amortization of Debt Discount (Premium) 3 month | Amortization of Debt Discount (Premium) 6 month | Amortization of Debt Discount (Premium) 9 month | Amortization of Debt Discount (Premium) 12 month |
|---|---|---|---|---|
| 2024-12-31 | $28.27K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-01 | $33.31K derived: sum of 2 quarters · filed 2026-04-01 | $38.30K derived: sum of 3 quarters · filed 2026-04-01 | $43.29K 10-K · filed 2026-04-01 |
| 2024-09-30 | $5.04K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $10.03K derived: sum of 2 quarters · filed 2025-11-14 | $15.01K 10-Q · filed 2025-11-14 | $20.05K derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $4.99K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-19 | $9.97K 10-Q · filed 2025-08-19 | $15.01K derived: sum of 3 quarters · filed 2025-08-19 | |
| 2024-03-31 | $4.99K 10-Q · filed 2025-05-15 | $10.03K derived: sum of 2 quarters · filed 2025-05-15 | ||
| 2023-12-31 | $5.04K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $16.71K 10-K · filed 2025-03-28 | ||
| 2023-09-30 | $11.67K 10-Q · filed 2024-12-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |